Michael C Arbushites Selected Research

itacitinib

1/2022	A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
1/2020	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael C Arbushites Research Topics

Disease

4	Breast Neoplasms (Breast Cancer) 08/2012 - 06/2008
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 01/2020
2	Exanthema (Rash) 12/2008 - 06/2008
2	Diarrhea 12/2008 - 06/2008
1	Necrosis 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2020
1	Pruritus (Itching) 06/2008
1	Nausea 06/2008

Drug/Important Bio-Agent (IBA)

4	Lapatinib (GW572016)FDA Link 08/2012 - 06/2008
2	itacitinibIBA 01/2022 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 08/2012 - 12/2008
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Janus Kinase 1IBA 01/2022
1	SteroidsIBA 01/2020
1	Endothelial Growth FactorsIBA 07/2012
1	Bevacizumab (Avastin)FDA Link 07/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2012
1	Epidermal Growth Factor (EGF)IBA 07/2012
1	Tyrosine Kinase InhibitorsIBA 12/2008
1	ErbB Receptors (EGF Receptor)IBA 12/2008
1	human ERBB2 proteinIBA 12/2008

Therapy/Procedure

2	Cell Transplantation 01/2020 - 01/2020
1	Therapeutics 06/2008